昂丹司琼联合倍他司汀治疗神经内科眩晕症患者的效果

Effects of Ondansetron combined with Betahistine in treatment of vertigo patients in department of neurology

目的:观察昂丹司琼联合倍他司汀治疗神经内科眩晕症患者的效果。方法:回顾性分析2018年2月至2019年3月该院收治的120例眩晕症患者的临床资料,根据用药方案不同分为对照组和观察组各60例。对照组采用倍他司汀治疗,观察组采用昂丹司琼联合倍他司汀治疗,比较两组临床疗效、治疗前后临床症状评分、眩晕障碍[眩晕残障程度评定量表(DHI)]评分,以及不良反应发生情况。结果:观察组治疗总有效率为93.33%(56/60),高于对照组的80.00%(48/60),差异有统计学意义(P<0.05);治疗后,观察组眩晕、恶心呕吐、头痛和平衡障碍等临床症状评分和DHI评分均低于对照组,差异有统计学意义(P<0.05);治疗期间,两组均未发生药物相关不良反应。结论:昂丹司琼联合倍他司汀治疗神经内科眩晕症患者可提高治疗总有效率,降低临床症状评分和DHI评分,效果优于单纯倍他司汀治疗。

Objective:To observe effects of Ondansetron combined with Betahistine in treatment of vertigo patients in department of neurology.Methods:The clinical data of 120 patients with vertigo treated in this hospital from February 2018 to March 2019 were retrospectively analyzed,and were divided into control group and observation group according to different medication regimens,60 cases in each.The control group was treated with Betahistine hydrochloride,while the observation group was treated with Ondansetron combined with Betahistine hydrochloride.The clinical efficacy,the clinical symptoms(dizziness,nausea and vomiting,headache and balance disorder)scores,the vertigo disorder[dizziness handicap inventory(DHI)]score,and the adverse reaction before and after the treatment were compared between the two groups.Results:The total effective rate of the observation group was 93.33%(56/60),which was higher than 80.00%(48/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the clinical symptom scores and the DHI scores of dizziness,nausea and vomiting,headache and balance disorder in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).During the treatment period,no drug-related adverse reactions occurred in both groups.Conclusions:Ondansetron combined with Betahistine in the treatment of the vertigo patients in department of neurology can improve the total effective rate of treatment,and reduce the clinical symptom score and the DHI score.Moreover,it is superior to single Betahistine hydrochloride.